CA2694284A1 - Heterocyclic compounds useful as raf kinase inhibitors - Google Patents

Heterocyclic compounds useful as raf kinase inhibitors Download PDF

Info

Publication number
CA2694284A1
CA2694284A1 CA2694284A CA2694284A CA2694284A1 CA 2694284 A1 CA2694284 A1 CA 2694284A1 CA 2694284 A CA2694284 A CA 2694284A CA 2694284 A CA2694284 A CA 2694284A CA 2694284 A1 CA2694284 A1 CA 2694284A1
Authority
CA
Canada
Prior art keywords
compound
optionally substituted
nitrogen
mmol
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2694284A
Other languages
English (en)
French (fr)
Inventor
Jennifer Cossrow
Bing Guan
Alexey Ishchenko
John Howard Jones
Gnanasambandam Kumaravel
Alexey Lugovskoy
Hairuo Peng
Noel Powell
Brian C. Raimundo
Hiroko Tanaka
Jeffrey Vessels
Thomas Wynn
Zhili Xin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Viracta Therapeutics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2694284A1 publication Critical patent/CA2694284A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CA2694284A 2007-06-29 2008-06-30 Heterocyclic compounds useful as raf kinase inhibitors Abandoned CA2694284A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94731907P 2007-06-29 2007-06-29
US60/947,319 2007-06-29
PCT/US2008/068789 WO2009006404A2 (en) 2007-06-29 2008-06-30 Heterocyclic compounds useful as raf kinase inhibitors

Publications (1)

Publication Number Publication Date
CA2694284A1 true CA2694284A1 (en) 2009-01-08

Family

ID=40015666

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2694284A Abandoned CA2694284A1 (en) 2007-06-29 2008-06-30 Heterocyclic compounds useful as raf kinase inhibitors

Country Status (8)

Country Link
US (1) US7968536B2 (OSRAM)
EP (1) EP2167497A2 (OSRAM)
JP (1) JP2010532381A (OSRAM)
CN (1) CN101743242A (OSRAM)
AU (1) AU2008273017C1 (OSRAM)
CA (1) CA2694284A1 (OSRAM)
NZ (1) NZ582349A (OSRAM)
WO (1) WO2009006404A2 (OSRAM)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI444379B (zh) * 2007-06-29 2014-07-11 Sunesis Pharmaceuticals Inc 有用於作為Ｒａｆ激酶抑制劑之化合物
MX2011002951A (es) * 2008-09-26 2011-04-26 Boehringer Ingelheim Int Compuestos de azaindazol como antagonistas del receptor de ccr1.
AU2009334997A1 (en) * 2008-12-30 2011-08-04 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as Raf kinase inhibitors
GB0910003D0 (en) 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
AR078793A1 (es) 2009-10-27 2011-12-07 Orion Corp Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros
JP5757956B2 (ja) 2009-11-20 2015-08-05 エスケー ケミカルス シーオー．， エルティーディー．Ｓｋ Ｃｈｅｍｉｃａｌｓ Ｃｏ．， Ｌｔｄ． ゴナドトロピン放出ホルモン受容体拮抗剤、その製造方法及びそれを含む医薬組成物
WO2012142029A2 (en) 2011-04-10 2012-10-18 Florida A&M University Serms for the treatment of estrogen receptor-mediated disorders
US9408885B2 (en) 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
CN104220428A (zh) 2012-02-03 2014-12-17 巴斯夫欧洲公司 杀真菌嘧啶化合物
EA201491667A1 (ru) 2012-03-13 2015-03-31 Басф Се Фунгицидные соединения пиримидина
CN102936251A (zh) * 2012-11-05 2013-02-20 上海毕得医药科技有限公司 一种吡咯并[2,3-d]嘧啶衍生物的制备方法
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
WO2014144747A1 (en) * 2013-03-15 2014-09-18 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
US9045477B2 (en) 2013-03-15 2015-06-02 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
CN105722833A (zh) 2013-09-16 2016-06-29 巴斯夫欧洲公司 杀真菌的嘧啶化合物
WO2015036059A1 (en) 2013-09-16 2015-03-19 Basf Se Fungicidal pyrimidine compounds
CN104761502A (zh) * 2014-01-03 2015-07-08 中国药科大学 苯并咪唑衍生物、其制法及医药用途
WO2015103901A1 (zh) * 2014-01-08 2015-07-16 上海交通大学医学院 硬脂酰氨基酸盐及其制备方法和应用
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
JP6246901B2 (ja) * 2015-01-14 2017-12-13 株式会社東芝 非水電解質電池及び電池パック
EP3185341B1 (fr) * 2015-12-21 2019-09-11 The Swatch Group Research and Development Ltd Cathode de pile métal/air et procédés de fabrication d'une telle cathode
JP2019196307A (ja) 2016-09-15 2019-11-14 武田薬品工業株式会社 複素環アミド化合物
AU2017329090B9 (en) 2016-09-19 2019-09-05 Novartis Ag Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor
EP3579872A1 (en) 2017-02-10 2019-12-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the mapk pathway
CN106928152A (zh) * 2017-03-03 2017-07-07 符爱清 一种尿嘧啶的制备方法
US11266653B2 (en) 2017-05-02 2022-03-08 Novartis Ag Combination therapy
KR102754527B1 (ko) 2017-05-30 2025-01-14 데이 원 바이오파마슈티칼즈, 인크. 광학 활성 화합물의 제조법
EP3687529B1 (en) 2017-09-27 2023-07-12 The Regents of the University of California Potent antiviral pyridine-containing compounds
WO2019133810A1 (en) 2017-12-28 2019-07-04 Tract Pharmaceuticals, Inc. Stem cell culture systems for columnar epithelial stem cells, and uses related thereto
EP3746422A4 (en) 2018-02-01 2021-06-09 The University Of Sydney ANTI-CANCER COMPOUNDS
CA3138123A1 (en) 2019-05-13 2020-11-19 Novartis Ag New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2 (trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
EP4074700A4 (en) 2019-12-10 2024-02-07 Shionogi & Co., Ltd HISTONE DEACETYLASE INHIBITOR COMPRISING AROMATIC HETEROCYCLIC GROUP CONTAINING NITROGEN
JP2023517519A (ja) * 2020-03-02 2023-04-26 シロナックス・リミテッド フェロトーシス阻害剤ジアリールアミンパラアセトアミド類
EP4188552A2 (en) * 2020-07-28 2023-06-07 Jazz Pharmaceuticals Ireland Limited Fused bicyclic raf inhibitors and methods for use thereof
EP4448492A1 (en) 2021-12-17 2024-10-23 Reglagene, Inc. Compositions and methods of making and using small molecules in the treatment of cancer
US12215102B2 (en) 2023-02-28 2025-02-04 Reglagene, Inc. Compositions and methods for making and using small molecules for tubulin-targeted therapy in the treatment of cancers and related conditions
CN117567388B (zh) * 2023-11-14 2024-04-16 济南悟通生物科技有限公司 一种2-乙酰基-5-噻唑甲酸的合成方法

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
US5563158A (en) * 1993-12-28 1996-10-08 The Dupont Merck Pharmaceutical Company Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
AU7095296A (en) * 1995-09-26 1997-04-17 Takeda Chemical Industries Ltd. Phosphorylamides, their preparation and use
US5760028A (en) * 1995-12-22 1998-06-02 The Dupont Merck Pharmaceutical Company Integrin receptor antagonists
CA2240439A1 (en) 1995-12-22 1997-07-03 The Dupont Merck Pharmaceutical Company Novel integrin receptor antagonists
US5872136A (en) * 1996-04-03 1999-02-16 Merck & Co., Inc. Arylheteroaryl inhibitors of farnesyl-protein transferase
CA2249607A1 (en) 1996-04-03 1997-10-09 Neville J. Anthony Inhibitors of farnesyl-protein transferase
US5877182A (en) * 1996-09-13 1999-03-02 Merck & Co., Inc. Piperidines promote release of growth hormone
US6174905B1 (en) 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
AUPO395396A0 (en) * 1996-12-02 1997-01-02 Fujisawa Pharmaceutical Co., Ltd. Benzamide derivatives
US6017925A (en) * 1997-01-17 2000-01-25 Merck & Co., Inc. Integrin antagonists
WO1998042323A1 (en) 1997-03-25 1998-10-01 Takeda Chemical Industries, Ltd. Stabilized urease inhibitor
AU6780398A (en) * 1997-03-28 1998-10-22 Du Pont Merck Pharmaceutical Company, The Heterocyclic integrin inhibitor prodrugs
SE9704545D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
US6632823B1 (en) * 1997-12-22 2003-10-14 Merck & Co., Inc. Substituted pyridine compounds useful as modulators of acetylcholine receptors
JPH11209366A (ja) 1998-01-23 1999-08-03 Nissan Chem Ind Ltd クロマン誘導体及び心不全治療薬
EP0982030A3 (en) * 1998-08-17 2000-05-10 Pfizer Products Inc. 2,7-substituted octahydro-pyrrolo 1,2-a]pyrazine derivatives as 5ht 1a ligands
CA2320730A1 (en) * 1998-12-23 2000-07-06 Renhua Li Thrombin or factor xa inhibitors
JP2002539124A (ja) 1999-03-10 2002-11-19 メルク エンド カムパニー インコーポレーテッド 性腺刺激ホルモン放出ホルモン拮抗薬としての６−アザインドール化合物
AU3514200A (en) * 1999-03-10 2000-09-28 Merck & Co., Inc. 6-azaindole compounds as antagonists of gonadotropin releasing hormone
WO2000058300A1 (en) 1999-03-25 2000-10-05 Nissan Chemical Industries, Ltd. Chroman derivatives
US6127382A (en) * 1999-08-16 2000-10-03 Allergan Sales, Inc. Amines substituted with a tetrahydroquinolinyl group an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity
EP1235807A1 (en) 1999-11-24 2002-09-04 Millennium Pharmaceuticals, Inc. B-amino acid-, aspartic acid- and diaminopropionic-based inhibitors of factor xa
GB0007245D0 (en) 2000-03-24 2000-05-17 Zeneca Ltd Chemical compounds
US6414013B1 (en) * 2000-06-19 2002-07-02 Pharmacia & Upjohn S.P.A. Thiophene compounds, process for preparing the same, and pharmaceutical compositions containing the same background of the invention
AU7002501A (en) 2000-06-21 2002-01-02 Du Pont Pharm Co Vitronectin receptor antagonist pharmaceuticals for use in combination therapy
US7259157B2 (en) * 2001-04-03 2007-08-21 Merck & Co., Inc. N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B Antagonists
ES2333702T3 (es) * 2001-12-24 2010-02-26 Astrazeneca Ab Derivados de quinazolina sustituidos que actuan como unhibidores de cinasas aurora.
TW200303304A (en) * 2002-02-18 2003-09-01 Astrazeneca Ab Chemical compounds
US20040048866A1 (en) * 2002-03-08 2004-03-11 Teodozyj Kolasa Indazole derivatives that are activators of soluble guanylate cyclase
US7202244B2 (en) * 2002-05-29 2007-04-10 Millennium Pharmaceuticals, Inc. Chk-1 inhibitors
WO2004000820A2 (en) * 2002-06-21 2003-12-31 Cellular Genomics, Inc. Certain aromatic monocycles as kinase modulators
JP4570955B2 (ja) * 2002-07-09 2010-10-27 バーテクス ファーマスーティカルズ インコーポレイテッド プロテインキナーゼ阻害活性を持つイミダゾール類
EP1400244A1 (en) * 2002-09-17 2004-03-24 Warner-Lambert Company LLC New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors
AU2003266607A1 (en) 2002-09-25 2004-04-19 Santen Pharmaceutical Co., Ltd. Therapeutic agent for rheumatism containing benzamide derivative as active ingredient
JP2004161716A (ja) 2002-11-15 2004-06-10 Takeda Chem Ind Ltd Ｊｎｋ阻害剤
MXPA05012281A (es) * 2003-05-14 2006-05-19 Torreypines Therapeutics Inc Compuestos y uso de los mismos en la modulacion beta amiloide.
JP2004339159A (ja) 2003-05-16 2004-12-02 Sankyo Co Ltd ４−オキソキノリン誘導体を含有する医薬組成物
DE10328999B4 (de) 2003-06-27 2006-08-31 Lanxess Deutschland Gmbh Verfahren zur Herstellung von Metallkomplexpigmenten mit niedriger Dispergierhärte
ATE370142T1 (de) * 2003-07-16 2007-09-15 Janssen Pharmaceutica Nv Triazolopyrimidinderivate als inhibitoren von glycogensynthasekinase-3
EA011300B1 (ru) * 2003-07-16 2009-02-27 Янссен Фармацевтика Н.В. Производные триазолопиримидина в качестве ингибиторов киназы гликогенсинтазы-3
EP1670771A4 (en) * 2003-09-30 2010-09-01 Irm Llc COMPOUNDS AND COMPOSITIONS INHIBITING PROTEIN-KINASES
GB2432834A (en) 2004-01-12 2007-06-06 Cytopia Res Pty Ltd Selective Kinase Inhibitors
US20050176733A1 (en) 2004-01-20 2005-08-11 Millennium Pharmaceuticals, Inc. Chk-1 inhibitors
TW200616974A (en) * 2004-07-01 2006-06-01 Astrazeneca Ab Chemical compounds
BRPI0513405A (pt) * 2004-07-16 2008-05-06 Sunesis Pharmaceuticals Inc tienopirimidinas úteis como inibidores de aurora quinase
EP2332527A3 (en) 2004-10-20 2011-11-16 Resverlogix Corp. Flavanoids and Isoflavanoids for the prevention and treatment of cardiovascular diseases
JP5111113B2 (ja) * 2004-12-13 2012-12-26 サネシス ファーマシューティカルズ， インコーポレイテッド Ｒａｆキナーゼ阻害剤として有用なピリドピリミジノン、ジヒドロピリミドピリミジノンおよびプテリジノン
JP5208516B2 (ja) 2004-12-30 2013-06-12 エグゼリクシス， インコーポレイテッド キナーゼモジュレーターとしてのピリミジン誘導体および使用方法
US7563781B2 (en) * 2005-01-14 2009-07-21 Janssen Pharmaceutica Nv Triazolopyrimidine derivatives
GB0501999D0 (en) 2005-02-01 2005-03-09 Sentinel Oncology Ltd Pharmaceutical compounds
TWI444379B (zh) * 2007-06-29 2014-07-11 Sunesis Pharmaceuticals Inc 有用於作為Ｒａｆ激酶抑制劑之化合物
AU2009334997A1 (en) 2008-12-30 2011-08-04 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as Raf kinase inhibitors

Also Published As

Publication number Publication date
AU2008273017A1 (en) 2009-01-08
JP2010532381A (ja) 2010-10-07
AU2008273017C1 (en) 2014-02-13
US20090005359A1 (en) 2009-01-01
CN101743242A (zh) 2010-06-16
WO2009006404A3 (en) 2009-07-30
AU2008273017B2 (en) 2013-10-10
US7968536B2 (en) 2011-06-28
NZ582349A (en) 2012-06-29
EP2167497A2 (en) 2010-03-31
WO2009006404A2 (en) 2009-01-08

Similar Documents

Publication Publication Date Title
AU2008273017C1 (en) Heterocyclic compounds useful as Raf kinase inhibitors
AU2008273002B2 (en) Pyrimidine derivatives useful as Raf kinase inhibitors
AU2009302360B2 (en) Imidazopyridazinecarbonitriles useful as kinase inhibitors
EP2379513A1 (en) Heteroaryl compounds useful as raf kinase inhibitors
CA3075751A1 (en) Pyrazolopyrimidinone compounds and uses thereof
CN108290879A (zh) 用作irak抑制剂的杂芳基化合物及其用途
EP2552922A1 (en) Substituted pyrrolotriazines as protein kinase inhibitors
EP2968339A1 (en) Mk2 inhibitors and uses thereof
CA3021185C (en) Fused heterocyclic compound
HK1143357A (en) Pyrimidine derivatives useful as raf kinase inhibitors
HK1143357B (en) Pyrimidine derivatives useful as raf kinase inhibitors
AU2014200030A1 (en) Pyrimidine Derivatives Useful as Raf Kinase Inhibitors

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130628

FZDE Discontinued

Effective date: 20150630